Xspray Pharma AB (6XP) Stock Statistics & Valuation Metrics
Total Valuation
Xspray Pharma AB has a market cap or net worth of EUR 50.76M. The enterprise value is EUR 645.43M.
- Market Cap
- EUR 50.76M
- Enterprise Value
- EUR 645.43M
Share Statistics
Xspray Pharma AB has 47,416,573 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 47,416,573
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Xspray Pharma AB’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -21.48%.
- Return on Equity (ROE)
- -0.28
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -21.48%
- Return on Capital Employed (ROCE)
- -0.22
- Revenue Per Employee
- 0
- Profits Per Employee
- -7.14M
- Employee Count
- 24
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.25
Valuation Ratios
The current PE Ratio of Xspray Pharma AB is -3.34. Xspray Pharma AB’s PEG ratio is -0.05.
- PE Ratio
- -3.34
- PS Ratio
- 0.00
- PB Ratio
- 0.93
- Price to FCF
- -3.78
- Price to Operating Cash Flow
- -3.92
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Xspray Pharma AB had revenue of 0 and earned -171.44M in profits. Earnings per share was -4.46.
- Revenue
- 0
- Gross Profit
- -5.58M
- Operating Income
- -161.85M
- Pretax Income
- -171.55M
- Net Income
- -171.44M
- EBITDA
- -156.27M
- Earnings Per Share (EPS)
- -4.46
Cash Flow
In the last 12 months, operating cash flow was -150.34M and capital expenditures -12.86M, giving a free cash flow of -161.72M billion.
- Operating Cash Flow
- -150.34M
- Free Cash Flow
- -161.72M
- Free Cash Flow per Share
- -3.53
Dividends & Yields
Xspray Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -26.48%
- Earnings Yield
- -27.02%
Stock Price Statistics
- Beta
- 1.22
- 52-Week Price Change
- -53.21%
- 50-Day Moving Average
- 0.89
- 200-Day Moving Average
- 1.64
- Relative Strength Index (RSI)
- 60.70
- Average Volume (3m)
- ―
Important Dates
Xspray Pharma AB upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Xspray Pharma AB as a current ratio of 8.44, with Debt / Equity ratio of 28.13%
- Current Ratio
- 8.44
- Quick Ratio
- 7.41
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -0.10
- Interest Coverage Ratio
- -9.60
Taxes
In the past 12 months, Xspray Pharma AB has paid -104.00K in taxes.
- Income Tax
- -104.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Xspray Pharma AB EV to EBITDA ratio is -4.36, with an EV/FCF ratio of -3.57.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.36
- EV to Free Cash Flow
- -3.57
- EV to Operating Cash Flow
- -3.85
Balance Sheet
Xspray Pharma AB has EUR 179.91M in cash and marketable securities with EUR 147.30M in debt, giving a net cash position of EUR 32.60M billion.
- Cash & Marketable Securities
- EUR 179.91M
- Total Debt
- EUR 147.30M
- Net Cash
- EUR 32.60M
- Net Cash Per Share
- EUR 0.69
- Tangible Book Value Per Share
- EUR 2.44
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Xspray Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 42.37%
